Tumori最新文献

{"title":"Effectiveness of carboplatin vs cisplatin in lung cancer chemo-immunotherapy: A systematic review and meta-analysis.","authors":"Alessandro Leonetti, Giuseppe Maglietta, Marianna Peroni, Francesca Diodati, Alessandra Dodi, Giulia Mazzaschi, Fabiana Perrone, Caterina Caminiti, Marcello Tiseo","doi":"10.1177/03008916261450355","DOIUrl":"https://doi.org/10.1177/03008916261450355","url":null,"abstract":"<p><p>IntroductionChemo-immunotherapy (CT-IT) currently represents the standard therapy for both non-small (NSCLC) and small cell lung cancer (SCLC). However, the differential impact of platinum compounds on immunotherapy outcomes remains to be determined.MethodsA systematic review was conducted to identify randomized controlled trials (RCTs) of combinations of immune check-point inhibitors (ICIs) and platinum-based chemotherapy (CT), providing separate outcome data for carboplatin and cisplatin. Since no direct comparison between the two platinum compounds was reported, a network meta-analysis was performed. The primary endpoints were overall survival (OS) and progression-free survival (PFS) for advanced NSCLC and SCLC and event-free survival (EFS) for early-stage NSCLC.ResultsEleven RCTs including 6125 patients were analyzed. In extensive-stage SCLC (four trials, 2663 patients), a non-significant trend toward improved OS was observed with cisplatin-based regimens (HR: 0.92, 95% CI 0.72-1.18; I²=47%). In advanced NSCLC (four trials, 1948 patients), a non-significant trend toward improved PFS was observed with carboplatin-based regimens (cisplatin vs carboplatin HR: 1.11, 95% CI 0.89-1.39; I²=0%). In early-stage NSCLC (three trials, 1514 patients), no differences emerged in EFS between subgroups (p=0.65 fixed-effect; p=0.49 random-effects).ConclusionsOur analysis does not demonstrate a statistically significant difference between cisplatin- and carboplatin-based CT-IT in lung cancer, although stage- and histology-specific numerical trends were observed. Given the absence of head-to-head comparisons and the lack of disaggregated baseline data, these findings should be considered exploratory.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261450355"},"PeriodicalIF":3.1,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148158301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alectinib and gastrointestinal perforation in ALK-rearranged non-small cell lung cancer: A case series.","authors":"Margherita Piccinelli, Raffaele Squitieri, Rebecca Romanò, Silvia Marchesi, Giulia Montelatici, Camilla Damonte, Marta Brambilla, Teresa Beninato, Laura Mazzeo, Giulia Corrao, Marco Meazza Prina, Arsela Prelaj, Claudia Proto, Margherita Galassi, Filippo Guglielmo Maria De Braud, Giuseppe Lo Russo, Mario Occhipinti, Paolo Ambrosini","doi":"10.1177/03008916261449595","DOIUrl":"https://doi.org/10.1177/03008916261449595","url":null,"abstract":"<p><strong>Background: </strong>Alectinib, a second-generation <i>ALK</i> inhibitor, is used in first-line and adjuvant treatment for <i>ALK-</i>rearranged NSCLC, and has proven to be both effective and well tolerated. Gastrointestinal (GI) perforation is an extremely rare but potentially life-threatening complication, with only sporadic cases reported in the literature.</p><p><strong>Methods: </strong>We describe, to the best of our knowledge, the largest case series to date of GI perforations that occurred during alectinib treatment in patients with <i>ALK-</i>rearranged NSCLC. Clinical features, management strategies, and outcomes were analyzed and integrated with available literature.</p><p><strong>Results: </strong>Three female patients developed GI perforation after variable durations of alectinib treatment, ranging from one month to over three years. Two cases were associated with pre-existing diverticulosis, while one occurred in the absence of any known GI comorbidities. Management included conservative treatment with intravenous antibiotics in two cases and surgical intervention in one. Alectinib was permanently discontinued in all patients. Subsequent therapeutic strategies included lorlatinib or brigatinib, with heterogeneous tolerability and outcomes. Literature review identified other reports of GI perforation or severe toxicity under alectinib.</p><p><strong>Conclusions: </strong>Although rare, GI perforation, represents a clinically relevant adverse event associated with alectinib, particularly in patients with diverticulosis or other predisposing conditions. It is essential to optimize safety and long-term disease control by raising awareness of early warning symptoms, conducting a baseline GI evaluation in high-risk patients and carefully sequencing therapy after discontinuation.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261449595"},"PeriodicalIF":3.1,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148158356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic effects of XPO1 inhibitors combined with CD19 CAR-T cells in TP53-mutated DLBCL.","authors":"Zhimin Bai, Xiaoyu Huang, Xinfeng Wang, Yong Zhou, Zenghua Lin, Hong Liu","doi":"10.1177/03008916251408273","DOIUrl":"10.1177/03008916251408273","url":null,"abstract":"<p><strong>Introduction: </strong>Diffuse large B-cell lymphoma (DLBCL) is mostly curable by chemotherapy, but p53 mutations limit the therapeutic effect of DLBCL. Although chimeric antigen receptor (CAR) T cells have made revolutionary progress in the treatment of DLBCL, p53 mutations still lead to drug resistance and/or relapse of DLBCL, affecting the prognosis of lymphoma. Therefore, the project aims to explore additional therapeutic strategies to improve the prognosis of DLBCL with p53 mutations.</p><p><strong>Methods: </strong>We investigated the correlation between XPO1 and mut-P53 employing qRT-PCR, WB, CCK8 and flow cytometry. Then, we conduct XPO1 inhibitor (KPT-330) to explore the apoptotic effect on DLBCL. Through the TCGA database, there is a clear correlation between XPO1-related genes and the PI3K-AKT pathway.</p><p><strong>Results: </strong>In this study, we showed that XPO1 inhibitor (KPT-330) synergized with CAR-T to reduce the viability of DLBCL and enhance the killing effect of CAR-T cells. As expected, KPT-330 combined with CAR-T therapy slowed tumor growth and reduced tumor burden in DLBCL with p53 mutations. Mechanistically, XPO1 inhibitor KPT-330 can cooperate with CAR-T in the treatment of DLBCL by activating the PI3K pathway. Then, in vitro cytotoxicity assays revealed that the KPT-330 combined with CAR-T group significantly enhanced the secretion of effector cytokines IFN-γ, TNF-α, and IL-2, and activated the immune system.</p><p><strong>Conclusions: </strong>The XPO1 inhibitor KPT-330 exerts anti-cancer effects through stabilizing p53 and inhibiting the PI3K-AKT pathway, providing a molecular basis for DLBCL treatment. We may provide a potential promising combination therapy for the treatment of DLBCL with p53 mutations.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"200-212"},"PeriodicalIF":3.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic and prognostic role of <i>GPX1</i> in NK/T cell lymphoma.","authors":"Wen Tang, Min Zhao, Juan He, Kuai Yu, Yanmei Tan, Tao Xie, Dan Li","doi":"10.1177/03008916261422175","DOIUrl":"10.1177/03008916261422175","url":null,"abstract":"<p><strong>Purpose: </strong>Natural killer/T-cell lymphoma (NKTCL) is an aggressive lymphoma. Glutathione peroxidase 1 (<i>GPX1</i>) is a prevalent isoform with reported roles in various tumors and prognostic implications. However, <i>GPX1</i>'s role in NKTCL remains unclear. This study's aim is to explore the association of <i>GPX1</i> expression with NKTCL.</p><p><strong>Methods: </strong>To explore <i>GPX1</i> expression in NKTCL, we employed GEO2R to identify DEGs (Differentially-expressed genes) from GSE80632 (NKTCL and normal samples) in the Gene Expression Omnibus (GEO). Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was employed to perform the biological processes enrichment. Immunohistochemistry (IHC) confirmed <i>GPX1</i> expression in 76 NKTCL cases. Kaplan-Meier survival curves assessed OS, while Cox regression and Logistic analyses studied <i>GPX1</i>'s clinical associations.</p><p><strong>Results: </strong><i>GPX1</i>, among the top ten of 3362 DEGs, distinguished NKTCL from normal tissue. High <i>GPX1</i> expression correlated with advanced-stage disease and poor initial treatment outcomes. Logistic analysis found no significant clinical feature association. Patients with high <i>GPX1</i> expression had lower OS.</p><p><strong>Conclusion: </strong><i>GPX1</i> could serve as a diagnostic and prognostic biomarker for NKTCL patients.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"213-220"},"PeriodicalIF":3.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer prevention and cancer avoidance: Challenges and opportunities.","authors":"Giovanni Apolone, Maria Teresa Montella, Gianluca Severi, Giulio Pompilio","doi":"10.1177/03008916251404224","DOIUrl":"10.1177/03008916251404224","url":null,"abstract":"<p><p>Despite innovations in diagnosis and treatment that have increased our ability to control cancer, it remains the second leading cause of death in Europe and is the principal cause in the under-65s. According to Eurostat, cancer accounted for 30.6% of all deaths in this age group in 2021, 40.6% for women and 25.6% for men.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"188-191"},"PeriodicalIF":2.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147514947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Choriocarcinoma: Diagnosis, treatment and management of a rare germ cell tumour. An update review.","authors":"Pierantoni Francesco, Fabiana Caliciotti, Selma Ahcene Djaballah, Eleonora Lai, Davide Bimbatti, Silvia Stragliotto, Ilaria Zampiva, Melissa Ballestrin, Chiara Pittarello, Salim Jubran, Greta Pretto, Elisa Erbetta, Anna Milani, Umberto Basso, Marco Maruzzo","doi":"10.1177/03008916251408266","DOIUrl":"10.1177/03008916251408266","url":null,"abstract":"<p><p>Choriocarcinoma is a malignant neoplasia which develops from trophoblastic cells. In males it is rare and often associated with other non-seminomatous germ cell tumours of the testis. Choriocarcinoma often presents with metastatic disease and elevated βHCG levels. Usually, patients' symptoms are associated with the different metastatic sites and they can be severe or even life-threatening. Moreover, choriocarcinoma is chemosensitive and the administration of chemotherapy with curative intent may lead to tumour-lysis syndrome and the more specific choriocarcinoma syndrome (CS). Therefore, the treatment of metastatic choriocarcinoma is complex, involving both oncological therapy and the management of acute complications. This review explores choriocarcinoma in males, focusing on its clinical presentation, pathogenetic mechanisms, and treatment options, including investigational therapies. Additionally, we aim to highlight the severe complications of CS and discuss its management strategies.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"192-199"},"PeriodicalIF":2.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13250271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147277331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ALYREF promotes laryngeal cancer progression through a lactate-mediated lactylation feedback loop that enhances glycolysis.","authors":"Shanyan Bian, Yingwei Guo, Rui Li, Yingtao Wu, Jianqi Zhao, Jiancong Huang","doi":"10.1177/03008916261417937","DOIUrl":"10.1177/03008916261417937","url":null,"abstract":"<p><strong>Objective: </strong>As a serious malignancy of the head and neck region, laryngeal cancer (LC) exhibits active glycolysis that produces lactate, a metabolite capable of inducing protein lactylation. However, the role of lactate-induced modifications in LC progression remains poorly understood. Although ALYREF has been identified as an oncogenic driver in several cancers, its function in LC has not yet been investigated.</p><p><strong>Methods: </strong>Malignant cell behaviors were assessed using Cell Counting Kit-8, EdU staining, glucose uptake, lactate production, and extracellular acidification rate (ECAR) assays. The experimental methodology also included quantitative real-time PCR, western blot, and xenograft tumor models.</p><p><strong>Results: </strong>Data demonstrated that ALYREF is markedly overexpressed in LC and holds potential diagnostic value. Knockdown of ALYREF impaired both proliferation and glycolytic capacity in LC cells. Mechanistically, increased lactate levels promoted lactylation of ALYREF at the K171 site, which in turn enhanced ALYREF expression. Elevated lactate concentrations rescued the suppression of oncogenic phenotypes and glycolysis induced by ALYREF reduction. Furthermore, in vivo experiments confirmed that ALYREF silencing inhibited tumor growth.</p><p><strong>Conclusions: </strong>Our findings indicate that ALYREF promotes tumor progression by enhancing glycolysis. Glycolysis-derived lactate stabilizes the ALYREF protein via lactylation at K171, establishing a positive feedback loop that drives LC malignancy. Silencing ALYREF suppresses tumor growth, underscoring its potential as a therapeutic target in LC.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"231-240"},"PeriodicalIF":3.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146143577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survey among childhood cancer survivors about their preferences on functionalities of a to-be-developed Survivorship Passport Mobile App.","authors":"Sara Oberti, Giorgia Manuzi, Martina Fragola, Hannah Gsell, Monica Muraca, Andrea Beccaria, Anita Kienesberger, Carina Schneider, Zuzana Tomasikova, Jack Latteur, Leontien C M Kremer, Riccardo Haupt, Ramona Tallone","doi":"10.1177/03008916261425443","DOIUrl":"10.1177/03008916261425443","url":null,"abstract":"<p><strong>Objective: </strong>Investigate preferences of childhood cancer survivors (CCS) or of their caregivers (CG) about functionalities of a to be developed mobile app intended to improve compliance with a personalized survivorship care plan (Survivorship Passport) delivered according to the PanCareFollowUp model.</p><p><strong>Study setting and design: </strong>A 19-item Likert-type questionnaire was distributed by Childhood Cancer International among its affiliated associations. App functionalities were grouped into four modules (My Passport; My Hospital; Communication/Telehealth; My Health) and assigned to one of the Quality of cancer Survivorship Care Framework (QCSCF) domains.Data source and analytic sample:A decreasing score was given to each answer with \"very useful\" having the score of 4 and \"not useful\" the score of 1. Response data were reported with their mean (μ) score and values >3.5, between 3.2 - 3.5, 2.6 - 3.1 and <3.1 were defined as \"very appreciated\" \"appreciated\", \"fairly appreciated\" and \"not appreciated\", respectively.</p><p><strong>Principal findings: </strong>One hundred and fifty-four subjects (55% CG) completed the survey. Six functionalities were very appreciated and belonged either to the My Passport (n=3), My Hospital (n=2) or Communication/Telehealth (n=1) modules. Nine functionalities were appreciated (Communication/Telehealth n=6, My Passport n=3). Functionalities of the My Health module were the least appreciated. When functionalities were pooled according to the QCSCF, those pertinent to the health care delivery contextual domain were very appreciated, while those related to cancer and its treatment were not appreciated.</p><p><strong>Conclusions: </strong>This survey provided useful information which contributed to the development of the Cancer Survio Smart Card prototype by the SmartCARE consortium.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"268-276"},"PeriodicalIF":2.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13250270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147782154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The clinical usefulness of knowing <i>CHRNA5</i> polymorphism genotype: paving the way for personalized therapy.","authors":"Francesca Colombo, Chiara Veronese, Elena Munarini, Cinzia Paolino, Davide Maspero, Nunzia Mangano, Martina Esposito, Francesca Minnai, Sara Noci, Marta Giussani, Daniele Morelli, Elisa Cardani, Alessandro Esposito, Gaia Giulia Angela Sacco, Debora Spitaleri, Roberto Boffi","doi":"10.1177/03008916251408279","DOIUrl":"10.1177/03008916251408279","url":null,"abstract":"<p><strong>Background: </strong>Tobacco smoking is a leading cause of global mortality, with cessation being the primary prevention strategy. Nicotine addiction has a genetic component; the rs503464 single nucleotide polymorphism (SNP) in the <i>CHRNA5</i> gene is associated with smoking cessation therapy success. However, the impact of communicating genetic risk to patients remains unclear. This study evaluated whether knowledge of the rs503464 genotype influences smoking cessation rates.</p><p><strong>Methods: </strong>270 smokers were enrolled and randomized into two groups: informed and uninformed of their rs503464 genotype. All participants received standard pharmacological-behavioral interventions. Cessation rates were assessed at 1, 3, 6, and 12 months. Multivariable logistic regression models analyzed the effect of knowing the rs503464 genotype and other variables on cessation success.</p><p><strong>Results: </strong>Among the 219 subjects who started prescribed smoking cessation medication, no significant differences in cessation rates were observed between participants informed or not informed of their rs503464 genotype at any follow-up point (P > 0.05). Male gender and higher baseline carbon monoxide levels were associated with lower success rates at three months. The medications used were equally effective.</p><p><strong>Conclusions: </strong>Communication of the rs503464 genotype did not influence smoking cessation success, proving that it does not disturb this process. This result opens the possibility of using genetic information to personalize anti-smoking treatment.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"221-230"},"PeriodicalIF":2.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13250266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147435838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and selection of the best artificial intelligence methods developed for detection and diagnosis of breast cancer.","authors":"Xuan Zhou, Qi Fan, Dan Zhu, Jing Kang, Lijun Lv","doi":"10.1177/03008916261434125","DOIUrl":"10.1177/03008916261434125","url":null,"abstract":"<p><strong>Background: </strong>Comprehensive identification and prioritization of developed artificial intelligence methods for the detection and diagnosis of breast cancer can help to select proper techniques. This study aimed to introduce the best artificial intelligence techniques developed for the detection and diagnosis of breast cancer using microscopic images by fuzzy AHP-TOPSIS techniques.</p><p><strong>Methods: </strong>To identify the artificial intelligence techniques developed, a systematic search was performed in five reliable databases. After that, the Delphi method was applied to determine the proper criteria for selecting the best artificial intelligence techniques. To estimate the relative weights of the criteria, the fuzzy analytical hierarchy process (FAHP) method was used. In the next step, to prioritize the identified artificial intelligence techniques, the technique for order of preference by similarity to the ideal solution (TOPSIS) method was applied.</p><p><strong>Results: </strong>Forty-four artificial intelligence techniques were identified. Seven selection criteria, validity, accuracy, comprehensiveness, processing time, cost, simplicity, and executive capability, were introduced. Ensemble deep learning architectures integrated with web of things (weight = 0.8041), the computer-aided diagnosis method (weight = 0.7774), the ensemble strategy (VGG16 - ResNet34 - ResNet50) (weight = 0.7475), automated tumor-stroma interface zone detection (weight = 0.7475), and MultiNet/Computer-Aided Diagnosis (CAD)-based deep learning model (weight = 0.7262) were selected as the best methods, respectively.</p><p><strong>Conclusion: </strong>These findings represent a total approach to the developed techniques which can be used for designing methods with better performance in the future.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"241-259"},"PeriodicalIF":2.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}